Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. (Q48082976)
Jump to navigation
Jump to search
scientific article published in May 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. |
scientific article published in May 2014 |
Statements
1 reference
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. (English)
1 reference
Ebrahim S Delpassand
1 reference
Amin Samarghandi
1 reference
Sara Zamanian
1 reference
Edward M Wolin
1 reference
Mohammadali Hamiditabar
1 reference
Gregory D Espenan
1 reference
Jack L Erion
1 reference
Larry K Kvols
1 reference
Jaime Simon
1 reference
Robert Wolfangel
1 reference
Arthur Camp
1 reference
Eric P Krenning
1 reference
Alireza Mojtahedi
1 reference
1 May 2014
1 reference
1 reference
43
1 reference
4
1 reference
518-525
1 reference
Identifiers
1 reference
1 reference